[go: up one dir, main page]

BR9916732A - Derivados de ácido malÈnico, processo para a sua preparação, seu uso e composições farmacêuticas contendo-os (inibição da atividade do fator xa) - Google Patents

Derivados de ácido malÈnico, processo para a sua preparação, seu uso e composições farmacêuticas contendo-os (inibição da atividade do fator xa)

Info

Publication number
BR9916732A
BR9916732A BR9916732-8A BR9916732A BR9916732A BR 9916732 A BR9916732 A BR 9916732A BR 9916732 A BR9916732 A BR 9916732A BR 9916732 A BR9916732 A BR 9916732A
Authority
BR
Brazil
Prior art keywords
formula
factor
inhibition
activity
preparation
Prior art date
Application number
BR9916732-8A
Other languages
English (en)
Inventor
Elisabeth Defossa
Uwe Heinelt
Otmar Klingler
Gerhard Zoller
Hans Matter
Fahad A Al-Obeidi
Armin Walser
Peter Wildgoose
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99100002A external-priority patent/EP1016663A1/en
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR9916732A publication Critical patent/BR9916732A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Patente de Invenção: <B>"DERIVADOS DE áCIDO MALÈNICO, PROCESSO PARA A SUA PREPARAçãO, SEU USO E COMPOSIçõES FARMACêUTICAS CONTENDO-OS (INIBIçãO DA ATIVIDADE DO FATOR XA)"<D>. A presente invenção refere-se a novos compostos para a inibição de proteínas de coagulação do sangue, e mais particularmente, a derivados de ácido malónico da fórmula (I), em que R(1), R(2), R(3), R(4), R(5) e R(6) têm os significados indicados nas reivindicações. Os compostos de fórmula I são inibidores do fator Xa da enzima de coagulação do sangue. A invenção também refere-se a processos para a preparação dos compostos de fórmula I, a métodos de inibição da atividade do fator Xa e de inibição da coagulação do sangue, ao uso dos compostos de fórmula I no tratamento e profilaxia de doenças, que podem ser tratadas ou prevenidas pela inibição da atividade do fator Xa tais como doenças tromboembólicas, e ao uso dos compostos de fórmula I na preparação de medicamentos a serem aplicados em tais doenças. A invenção ainda refere-se a composições contendo um composto de fórmula I em mistura ou de outro modo em associação com um veículo inerte, em particular composições farmacêuticas contendo um composto de fórmula I juntamente com substâncias veículose substâncias auxiliares farmaceuticamente aceitáveis.
BR9916732-8A 1999-01-02 1999-12-23 Derivados de ácido malÈnico, processo para a sua preparação, seu uso e composições farmacêuticas contendo-os (inibição da atividade do fator xa) BR9916732A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99100002A EP1016663A1 (en) 1999-01-02 1999-01-02 Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity)
EP99119537 1999-10-01
PCT/EP1999/010340 WO2000040571A1 (en) 1999-01-02 1999-12-23 Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity)

Publications (1)

Publication Number Publication Date
BR9916732A true BR9916732A (pt) 2001-09-25

Family

ID=26152843

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916732-8A BR9916732A (pt) 1999-01-02 1999-12-23 Derivados de ácido malÈnico, processo para a sua preparação, seu uso e composições farmacêuticas contendo-os (inibição da atividade do fator xa)

Country Status (17)

Country Link
US (1) US6395737B1 (pt)
EP (1) EP1140878A1 (pt)
JP (1) JP2002534420A (pt)
KR (1) KR20010101355A (pt)
CN (1) CN1332734A (pt)
AU (1) AU3043100A (pt)
BR (1) BR9916732A (pt)
CA (1) CA2358578A1 (pt)
CZ (1) CZ20012379A3 (pt)
HK (1) HK1041700A1 (pt)
HU (1) HUP0105437A3 (pt)
ID (1) ID29979A (pt)
IL (1) IL144096A0 (pt)
NO (1) NO20012983D0 (pt)
PL (1) PL349343A1 (pt)
TR (1) TR200101903T2 (pt)
WO (1) WO2000040571A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69924527T2 (de) 1999-01-02 2006-02-09 Sanofi-Aventis Deutschland Gmbh Arylalkanoylderivate, verfahren zu ihrer herstellung, ihre verwendung und diese enthaltende pharmazeutische zubereitungen
EP1127884A1 (en) * 2000-02-26 2001-08-29 Aventis Pharma Deutschland GmbH Novel malonic acid derivatives, processes for their preparation, their use as inhibitor of factor XA activity and pharmaceutical compositions containing them
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
DK1569912T3 (en) 2002-12-03 2015-06-29 Pharmacyclics Inc 2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors.
US9279022B1 (en) 2014-09-08 2016-03-08 Sirrus, Inc. Solution polymers including one or more 1,1-disubstituted alkene compounds, solution polymerization methods, and polymer compositions
US9828324B2 (en) 2010-10-20 2017-11-28 Sirrus, Inc. Methylene beta-diketone monomers, methods for making methylene beta-diketone monomers, polymerizable compositions and products formed therefrom
US8884051B2 (en) 2010-10-20 2014-11-11 Bioformix Inc. Synthesis of methylene malonates using rapid recovery in the presence of a heat transfer agent
US10414839B2 (en) 2010-10-20 2019-09-17 Sirrus, Inc. Polymers including a methylene beta-ketoester and products formed therefrom
US9249265B1 (en) 2014-09-08 2016-02-02 Sirrus, Inc. Emulsion polymers including one or more 1,1-disubstituted alkene compounds, emulsion methods, and polymer compositions
TWI633091B (zh) 2011-10-14 2018-08-21 Bristol-Myers Squibb Company 作為因子ｘｉａ抑制劑之經取代四氫異喹啉化合物
US9108951B2 (en) 2011-10-14 2015-08-18 Bristol-Myers Squibb Company Substituted 5,6,7,8-tetrahydro-1,6-naphthyridines as factor XIa inhibitors
IN2014CN02805A (pt) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
EP3517523A1 (en) 2011-10-19 2019-07-31 Sirrus, Inc. Multifunctional monomers and methods for making them
EP2831124B1 (en) 2012-03-30 2016-10-05 Sirrus, Inc. Composite and laminate articles and polymerizable systems for producing the same
CA2869115A1 (en) 2012-03-30 2013-10-03 Bioformix Inc. Ink and coating formulations and polymerizable systems for producing the same
EP2831125B1 (en) 2012-03-30 2016-10-05 Sirrus, Inc. Methods for activating polymerizable compositions, polymerizable systems, and products formed thereby
US10047192B2 (en) 2012-06-01 2018-08-14 Sirrus, Inc. Optical material and articles formed therefrom
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2906552B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
SI2906551T1 (en) 2012-10-12 2018-05-31 Bristol-Myers Squibb Company Crystalline forms of a factor xia inhibitor
CN105008438B (zh) 2012-11-16 2019-10-22 拜奥福米克斯公司 塑料粘结体系及方法
WO2014085570A1 (en) 2012-11-30 2014-06-05 Bioformix, Inc. Composite compositions for electronics applications
CN110204441A (zh) 2013-01-11 2019-09-06 瑟拉斯公司 经过双(羟甲基)丙二酸酯的途径获得亚甲基丙二酸酯的方法
US9738655B2 (en) 2013-03-25 2017-08-22 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors
NO2760821T3 (pt) 2014-01-31 2018-03-10
BR112016015717B1 (pt) 2014-01-31 2023-04-04 Bristol-Myers Squibb Company Compostos macrociclos com grupos p2' heterocíclicos como inibidores do fator xia, composição farmacêutica compreendendo os referidos compostos e uso dos mesmos
CA2952968A1 (en) 2014-07-01 2016-01-07 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP6526796B2 (ja) 2014-09-04 2019-06-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｆｘｉａ阻害剤であるジアミドマクロ環
US9416091B1 (en) 2015-02-04 2016-08-16 Sirrus, Inc. Catalytic transesterification of ester compounds with groups reactive under transesterification conditions
US9315597B2 (en) 2014-09-08 2016-04-19 Sirrus, Inc. Compositions containing 1,1-disubstituted alkene compounds for preparing polymers having enhanced glass transition temperatures
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
US10501400B2 (en) 2015-02-04 2019-12-10 Sirrus, Inc. Heterogeneous catalytic transesterification of ester compounds with groups reactive under transesterification conditions
US9334430B1 (en) 2015-05-29 2016-05-10 Sirrus, Inc. Encapsulated polymerization initiators, polymerization systems and methods using the same
US9217098B1 (en) 2015-06-01 2015-12-22 Sirrus, Inc. Electroinitiated polymerization of compositions having a 1,1-disubstituted alkene compound
US9518001B1 (en) 2016-05-13 2016-12-13 Sirrus, Inc. High purity 1,1-dicarbonyl substituted-1-alkenes and methods for their preparation
US9617377B1 (en) 2016-06-03 2017-04-11 Sirrus, Inc. Polyester macromers containing 1,1-dicarbonyl-substituted 1 alkenes
US10428177B2 (en) 2016-06-03 2019-10-01 Sirrus, Inc. Water absorbing or water soluble polymers, intermediate compounds, and methods thereof
US10196481B2 (en) 2016-06-03 2019-02-05 Sirrus, Inc. Polymer and other compounds functionalized with terminal 1,1-disubstituted alkene monomer(s) and methods thereof
US9567475B1 (en) 2016-06-03 2017-02-14 Sirrus, Inc. Coatings containing polyester macromers containing 1,1-dicarbonyl-substituted 1 alkenes

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE235866C (pt)
DE242404C (pt)
DK425382A (da) * 1981-09-25 1983-03-26 Wellcome Found Fremgangsmaade til fremstilling af amider
CA2073776A1 (en) 1990-11-15 1992-05-16 Joerg Stuerzebecher Meta-substituted phenyl alanine derivatives
IT1254883B (it) * 1992-04-16 1995-10-11 Italfarmaco Spa Tetrapeptidi parzialmente modificati e retroinvertiti, analoghi di frammenti della proteina c-reattiva.
CZ245994A3 (en) 1993-02-10 1995-10-18 Pentapharm Ag Piperazides of substituted phenylalanine derivatives as thrombin inhibitors
US5977074A (en) * 1993-10-01 1999-11-02 Merrell Pharmaceuticals, Inc. Inhibitors of β-amyloid protein production
SI9520044B (sl) * 1994-04-26 2004-08-31 Aventis Pharmaceuticals Inc. Inhibitorji Xa faktorja
AU3107795A (en) * 1994-08-09 1996-03-07 Pentapharm Ag Inhibitors of the benzamidine type
GB9420763D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc Acetamide derivatives
CN1087349C (zh) * 1995-12-20 2002-07-10 阿温蒂斯药物公司 N－乙酰基－(L)－4－氰基苯丙氨酸Ac-(L)-Phe(4－CN)－OH与N－乙酰基－(L)－对脒基苯丙氨酸－环己基甘氨酸－β－（3－N－甲基吡啶鎓）－丙氨酸AC－（L）－PAPh－chg－PaIMe(3)-NH2的新颖的制备方法
HUP0002942A3 (en) 1997-05-02 2001-12-28 Akzo Nobel Nv Peptides having serine protease inhibiting effect pharmaceutical compositions comprising thereof and their use
KR100608472B1 (ko) 1997-12-24 2006-08-09 사노피-아벤티스 도이칠란트 게엠베하 인자 Ｘａ의 억제제로서의 인돌 유도체 및 이를 함유하는 약제학적 조성물
EP1016663A1 (en) 1999-01-02 2000-07-05 Aventis Pharma Deutschland GmbH Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity)

Also Published As

Publication number Publication date
CZ20012379A3 (cs) 2001-09-12
WO2000040571A1 (en) 2000-07-13
CN1332734A (zh) 2002-01-23
PL349343A1 (en) 2002-07-15
AU3043100A (en) 2000-07-24
TR200101903T2 (tr) 2001-11-21
HK1041700A1 (zh) 2002-07-19
NO20012983L (no) 2001-06-15
KR20010101355A (ko) 2001-11-14
NO20012983D0 (no) 2001-06-15
EP1140878A1 (en) 2001-10-10
US6395737B1 (en) 2002-05-28
IL144096A0 (en) 2002-05-23
HUP0105437A3 (en) 2003-03-28
CA2358578A1 (en) 2000-07-13
HUP0105437A2 (hu) 2002-05-29
JP2002534420A (ja) 2002-10-15
ID29979A (id) 2001-10-25

Similar Documents

Publication Publication Date Title
BR9916732A (pt) Derivados de ácido malÈnico, processo para a sua preparação, seu uso e composições farmacêuticas contendo-os (inibição da atividade do fator xa)
BR0108694A (pt) Derivados de ácido malÈnico, processo para preparação dos mesmos, uso dos mesmos como inibidor de atividade do fator xa e composições farmacêuticas que contêm os mesmos
BR9814340A (pt) Derivados de indol como inibidores de fator xa
KAKEGAWA et al. Inhibitory effects of tannins on hyaluronidase activation and on the degranulation from rat mesentery mast cells
BR9806870A (pt) Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, formulação farmacêutica, e, uso de um composto e processo para preparar o mesmo.
BR0209821A (pt) Compostos, processo para a manufatura desses compostos, composições farmacêuticas que compreendem os mesmos, processo para o tratamento e/ou profilaxia de enfermidades e utilização dos compostos
MXPA04012965A (es) Inhibidores virales.
ATE388951T1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
BR9910849A (pt) Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, tal como um humano, formulação farmacêutica, uso de um composto, processo para preparação do composto, e, derivado protegido.
BR9810592A (pt) Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
BRPI0409227B8 (pt) &#34;composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)&#34;
BR0316234A (pt) Hidroxiindóis, seu uso como inibidores de fosfodiesterase 4 e processos para a preparação dos mesmos
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
WO1998056761A3 (en) Benzimidazole derivatives
BRPI0409498A (pt) uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto
BR9910573A (pt) Compostos antipicornavirais, preparação e uso dos mesmos
PL359584A1 (en) Factor viia inhibitory (thio)urea derivatives, their preparation and their use
BR0313459A (pt) Derivados monocìclicos como inibidores de metaloproteinases de matriz
MD1688F2 (en) Benzothiophene, benzofuran and indolethiazepinons, oxazepinons and diazepinons, pharmaceutical composition, method of inhibiting the leucocytes adherence to the endothelial cells for inflammatory diseases treatment and method of treatment of the mammals affected by the HIV infection
BR9713921A (pt) Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa
AU1185801A (en) Novel compounds
BR9809234A (pt) Composto, composição farmacêutica, uso de um composto, processos para tratar ou prevenir doenças do sistema endocrinológico, para fabricar um medicamento, para preparar um composto e um conjunto, conjunto, e, uso do mesmo.
BR0011461A (pt) Inibidores do fator viia
DK1115697T3 (da) Umættede hydroximsyrederivater som PARP-inhibitorer
BR9916733A (pt) Derivados de arilalcanoìla, processos para sua preparação, seu uso e composições farmacêuticas que os contêm

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5O, 6O E 7O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.